Many different mechanical and tissue prostheses are now available for aortic valve replacement and although efforts continue to be made to design durable heart valve prostheses that are free from valve related complications the debate continues about the reported advantages of low profile prostheses or biological valves compared with caged ball valves.' The long term structural durability and consistent long term integrity of xenografts have yet to be demonstrated.2 Mechanical heart valve prostheses have reasonable records of structural durability but this advantage is compromised by the risk of thromboembolism and the need for indefinite anticoagulation with its inherent risks.34 In patients with chronic mitral valve disease, indefinite anticoagulation is frequently necessary whether or not mitral valve operation is undertaken, and mechanical prostheses are usually chosen for mitral valve replacement because they are more durable than xenografts. Patients Twenty four patients required reoperation (1 49%/patient-year) (table 3) . The causes were thromboembolism in nine patients, prosthetic valve endocarditis in eight (with some but haemodynamically not severe paraprosthetic regurgitation in three of these), and severe paraprosthetic regurgitation without infection in seven. In all but one patient (with paraprosthetic regurgitation), reoperation was performed within 12 months of the original aortic valve replacement. Three patients reoperated on for continuing infective endocarditis died at operation or shortly afterwards, and there was one late death (at one year) after reoperation for paraprosthetic regurgitation in a patient with Marfan's syndrome.
The incidence of mortality and valve related morbidity did not appear to be particularly high in any specific year. There were no significant differences evident between the 2400 and 1260 prostheses in the actuarial probability of mortality, valve related morbidity, or thromboembolic events. A consistent trend towards greater freedom from mortality and valve related complications, however, is apparent for the model 1260 prosthesis over the period compared with the 2400 prosthesis during (fig 3) . del (during 1974-78) .
but this was rarely spontaneous and usually a precipitating event could be identified and no serious sion bleeding complications were observed. Other sites of haemorrhage were intramesenteric and retroudy was performed to define the long term peritoneal (one patient each). Anticoagulant probnance characteristics of the modem series of lems associated with pregnancy, childbirth, or fetal dwards aortic valve prostheses and demon-abnormalities were not included in our analysis but that the structural durability of Starr-the number of women of childbearing age with Is models 2400 and 1260 aortic prostheses is Starr-Edwards prostheses in our series was small it. There were no reports of cases of mechan-and anticoagulant problems associated with function from failures such as poppet frac-unrelated (non-cardiac) operations were rare. The embolisation, strut fracture, ball variance, or low frequency of anticoagulant related haemorrhage iosis in situ. This accords with other studies in this study favourably compares with that of other long term follow up of the modem series of published series`and again may relate, in part, to dwards aortic prostheses, with no previous careful anticoagulant control. patients; in three cases this was fatal. A wide variety of organisms was responsible, and the variation in the interval between valve replacement and the development of infective endocarditis reflects the usual experience in series of prosthetic valve endocarditis. Six patients required reoperation for endocarditis on eleven occasions, illustrating the surgical difficulty of eradicating the organism when medical treated has failed.9 14 One patient required reoperation on four occasions for endocarditis, but now is well three years after the last operation.
Haemolysis requiring hospital admission or detailed outpatient management was recorded in only three patients. In only one patient was this associated with appreciable paraprosthetic regurgitation. Haemolysis per se was never an indication for reoperation in this series. Appreciable paraprosthetic regurgitation was noted in nine patients of whom seven required reoperation. In two cases paraprosthetic regurgitation appeared after reoperation for prosthetic valve endocarditis, a situation in which the risk ofprosthetic dehiscence is high. Reoperation for all but one of the patients (with prosthetic regurgitation) was necessary within the first year after Differences in mortality and valve related morbidity in our patients compared with other published series are unlikely to be explained by differences in patient populations, because our patients resembled those in other series in terms of sex, rhythm, functional class, aetiology, and pathology; however, our patients tended to be younger. [5] [6] [7] In one study the Starr-Edwards prostheses were implanted as a valve of second choice in patients with more complicated diagnoses and a high proportion of previous valve surgery which may account for their relatively poor outcome in that study.5 Apart from functional class, the severity of preoperative or postoperative valvar disease or myocardial function was not considered in this study, but we have no reason to suspect significant differences from other series which would explain differences in mortality or valve related complications.
Prosthesis related factors that determine mortality and morbidity include reliability, durability, and thromboembolism. No cases of mechanical prosthetic dysfunction were reported in this study, and the frequency of thromboembolism was low. Compared with mechanical protheses bioprostheses used for aortic valve replacement show a lower incidence of thromboembolism and are not associated with any anticoagulant related haemorrhages; but these advantages are compromised by the increasing need for reoperation because of primary tissue valve failure with time. The rate of primary tissue valve failure accelerates after six years when the incidence of reoperation exceeds that for mechanical aortic prostheses,22 and the incidence of primary tissue valve failure for hioprostheses is 
